A Study of BGB-11417 in Participants With Myeloid Malignancies
Key claim: A Phase 1/2 study is evaluating BGB-11417 (a BCL-2 inhibitor) as monotherapy and in combination with azacitidine for safety, tolerability, RP2D, and preliminary efficacy in AML, MDS, and MDS/MPN overlap patients.
Abstract
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
Why this matters
BCL-2 inhibition has reshaped AML therapy via venetoclax + HMA, but MDS/MPN overlap syndromes have only indirectly benefited through extrapolation. A next-generation BCL-2 inhibitor (BGB-11417) tested prospectively in this population — including in combination with azacitidine — adds to a small but growing pipeline of HMA-based combinations specifically inclusive of MDS/MPN overlap, where dedicated trial evidence remains scarce.